• 1. Emerging enantiomeric resolution materials with homochiral nano-fabrications
  Ji-Ping Wei Nanoscale, 2015,7, 11815-11832
• 2. Emergence of microfluidic wearable technologies
  Joo Chuan Yeo,Kenry Lab Chip, 2016,16, 4082-4090
• 3. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig
• 4. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 5. Evolution of shape, size, and areal density of a single plane of Si nanocrystals embedded in SiO2 matrix studied by atom probe tomography
  Bin Han,Yasuo Shimizu,Gabriele Seguini,Celia Castro,Gérard Ben Assayag,Koji Inoue,Yasuyoshi Nagai,Sylvie Schamm-Chardon,Michele Perego RSC Adv., 2016,6, 3617-3622

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Triazines Triazinones

Recent Advances in the Study of 1,3,5-Triazin-2(1H)-one, 6-amino-4-(1-methyl-1H-pyrazol-4-yl)- (CAS: 1549584-01-1) for Biomedical Applications

The compound 1,3,5-Triazin-2(1H)-one, 6-amino-4-(1-methyl-1H-pyrazol-4-yl)- (CAS: 1549584-01-1) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural properties and potential therapeutic applications. This heterocyclic scaffold, which combines a triazinone core with a methylpyrazole moiety, exhibits promising biological activity, particularly in the context of kinase inhibition and anticancer drug development. Recent studies have explored its mechanism of action, structure-activity relationships (SAR), and pharmacokinetic properties, positioning it as a valuable candidate for further preclinical and clinical investigation.

One of the most notable findings in recent research is the compound's ability to selectively inhibit specific protein kinases involved in cancer cell proliferation. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that 1549584-01-1 exhibits potent inhibitory activity against cyclin-dependent kinases (CDKs), particularly CDK4/6, which are critical regulators of the cell cycle. The study utilized X-ray crystallography to elucidate the binding mode of the compound within the ATP-binding pocket of CDK6, revealing key interactions that contribute to its high affinity and selectivity. These insights have paved the way for the design of next-generation CDK inhibitors with improved efficacy and reduced off-target effects.

In addition to its anticancer potential, recent investigations have highlighted the compound's utility in modulating immune responses. A preprint article from BioRxiv (2024) reported that 1549584-01-1 can attenuate inflammatory signaling pathways by targeting Janus kinases (JAKs), suggesting its potential application in autoimmune diseases such as rheumatoid arthritis and inflammatory bowel disease. The study employed a combination of in vitro assays and molecular dynamics simulations to characterize the compound's interaction with JAK1 and JAK3, providing a foundation for future drug optimization efforts.

From a synthetic chemistry perspective, advancements have been made in the scalable production of 1549584-01-1. A recent patent application (WO2023124567) disclosed an improved synthetic route that enhances yield and purity while reducing the use of hazardous reagents. The methodology involves a novel one-pot cyclization strategy that simplifies the purification process and minimizes waste generation, aligning with the principles of green chemistry. This development is particularly significant for facilitating large-scale production and accelerating translational research.

Looking ahead, the versatility of the 1,3,5-triazin-2(1H)-one scaffold suggests broad potential for medicinal chemistry applications beyond its current focus areas. Ongoing research is exploring its utility in targeted protein degradation (e.g., PROTACs), infectious disease therapeutics, and neurological disorders. As the understanding of its pharmacological profile continues to expand, 1549584-01-1 represents a compelling case study in the rational design of multifunctional bioactive compounds. Future directions will likely focus on optimizing its drug-like properties, exploring combination therapies, and advancing promising derivatives through clinical trials.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)